Cytomx Therapeutics (CTMX)CEO sold ~$23K

~$23K

Approx. value · 38K sh @ $0.599

995K

Holds after · shares reported

Traded

Mar 18, 2025

Filed

Mar 20, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 18, 2025 · this disclosureInsiderCEO sold ~$23K of CTMX shares in the open market

What came next

1. Mar 18, 2025Insider · 4 peopleInsiders: 4 sales (~$25K)
2. Jun 13, 2025InsiderCFO sold ~$4.8K of CTMX shares in the open market
3. Jun 16, 2025Insider · 3 peopleInsiders: 3 sales (~$215K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytomx Therapeutics

For Cytomx Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CTMX page.

Other recent filings by Sean A. Mccarthy, CEO

• SEC Form 4 at Cytomx Therapeutics (CTMX)Jun 17, 2025

The full history of Sean A. Mccarthy, CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cytomx Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 14, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRNov 14, 2025

Everything OQRO holds on this company is on its CTMX page.